Import from '@womanrx/components'

Is MK-677 (Ibutamoren) Legal in Maryland? A Women's Guide to Safe, Legal Access

What MK-677 (Ibutamoren) Actually Is

MK-677 is not a peptide in the strict chemical sense. It is a non-peptide, orally active growth hormone secretagogue that binds the ghrelin receptor (GHSR-1a), prompting the pituitary to release growth hormone (GH) and, consequently, insulin-like growth factor 1 (IGF-1). Researchers originally developed it to treat muscle wasting and GH deficiency, and a phase II trial published in the Journal of Clinical Endocrinology and Metabolism showed that 25 mg daily raised IGF-1 levels by roughly 60% in healthy older adults compared with placebo over two years.

That trial enrolled primarily older men and postmenopausal women, which means the data most people cite comes from a narrow demographic slice.

How it differs from injectable GH

Unlike recombinant human growth hormone (rhGH), MK-677 is taken orally. It stimulates endogenous GH pulses rather than replacing GH from outside, which some proponents argue produces a more physiological pattern. The mechanistic argument is sound; whether it translates to clinically meaningful benefits across diverse women is less clear.

Why the ghrelin receptor matters for women

Ghrelin is deeply tied to appetite, metabolic rate, and menstrual cycle regulation. GH secretion is sex-dimorphic: women already secrete more GH per day than men, with pulse amplitude tightly linked to estrogen levels. Estrogen amplifies GH secretion at the pituitary level, which means a compound that further stimulates GH pulsatility may behave differently across the menstrual cycle and across menopause transition than trials in older men would predict.

The Federal Legal Framework: Where MK-677 Actually Stands

The federal question is the one that governs Maryland most directly, and the answer is genuinely complicated.

Not a scheduled substance

The Drug Enforcement Administration (DEA) does not list MK-677 as a Schedule I through V controlled substance. The DEA controlled substances schedule does not name Ibutamoren. That means possession alone does not trigger federal drug trafficking statutes the way anabolic steroids or GHB would.

Not FDA-approved

The FDA has never approved MK-677 for any indication. Merck (then SmithKline Beecham) conducted phase I and II trials in the 1990s, but no NDA was ever submitted and approved. Without an approved NDA, MK-677 cannot be legally marketed as a drug in the United States.

The 503A/503B compounding restriction

This is the most practically important federal development for patients seeking compounded MK-677. In 2023, the FDA published its updated bulk drug substances list and declined to include MK-677 on the Category 1 list of substances that may be compounded under Section 503A (traditional pharmacies) or Section 503B (outsourcing facilities). A substance not on that list cannot lawfully be compounded for patient use by a licensed U.S. Pharmacy.

That single regulatory decision is what closes most of the "legal prescription compounding" door that women might expect to walk through.

The research-chemical market

Vendors selling MK-677 labeled "for research use only, not for human consumption" occupy a gray zone. The FDA has sent warning letters to companies selling unapproved drugs under research labels, and the FDA's guidance on unapproved new drugs makes clear that intent to use for human consumption can convert a "research chemical" into an unapproved new drug. Purchasing from these sources is not unambiguously legal, and the quality control is unverifiable.

Maryland State Law: What Applies Here

Maryland does not have a separate state scheduling statute that names MK-677. The Maryland Controlled Dangerous Substances Act mirrors federal scheduling, so because the DEA has not scheduled MK-677, Maryland has not either.

The Maryland Board of Pharmacy

The Maryland Board of Pharmacy licenses and oversees pharmacies operating in the state. A Maryland-licensed pharmacy cannot lawfully compound MK-677 for patient dispensing precisely because the FDA has not placed it on the 503A bulk list. The Board does not need its own separate rule; federal compounding law governs what licensed pharmacies may produce.

The Maryland Medical Practice Act

A Maryland-licensed physician, nurse practitioner, or other prescriber could theoretically write a prescription for MK-677, but without a legal compounding or dispensing pathway, that prescription cannot be filled at a Maryland pharmacy. The Maryland Medical Practice Act requires prescribers to act within a standard of care, and prescribing a substance with no approved route of dispensing raises professional liability questions.

Personal importation

The FDA's personal importation policy permits individuals to import small amounts of unapproved drugs for personal use under specific conditions, primarily when the product is for a serious condition, there is no comparable approved alternative, and the product poses no significant safety risk. MK-677 does not clearly meet those criteria for most use cases, and enforcement is discretionary.

What Legal Access Actually Looks Like in Maryland (and Where the Gaps Are)

Given the regulatory picture above, here is a practical framework for Maryland women who have been told MK-677 might help them:

Step 1: Get a thorough endocrine workup first. Before considering any GH secretagogue, you need baseline IGF-1, fasting insulin, fasting glucose, HbA1c, thyroid panel, and sex hormone labs (FSH, LH, estradiol, testosterone free and total). These baselines matter because MK-677 raises IGF-1 and worsens insulin resistance, and you need to know your starting point.

Step 2: Ask whether an FDA-approved treatment addresses the same need. For adult GH deficiency, FDA-approved recombinant GH (somatropin) products such as Norditropin or Genotropin are available with a proper diagnosis. For muscle loss in postmenopausal women, resistance training plus adequate protein (1.2 to 1.6 g/kg/day) and, where indicated, menopausal hormone therapy have documented evidence behind them.

Step 3: Consult a prescriber who understands the current compounding rules. Some telehealth and longevity clinics still advertise compounded MK-677. Before you pay a consultation fee, ask directly: "Is the pharmacy you use 503B-registered and does it hold MK-677 on its formulary?" If the answer is vague, that is a red flag. As of the date of this article, no 503B outsourcing facility openly lists MK-677 as a legal compoundable item.

Step 4: If you choose an off-label research-chemical route, understand the risks explicitly. Product purity is unverifiable. A 2020 analysis of 44 "peptide" products purchased online found 44% of products contained a different substance or dose than labeled. That kind of error in a GH secretagogue with real metabolic effects is not trivial.

MK-677 and Women's Physiology: What the Evidence Actually Shows

Most MK-677 trials enrolled men or older mixed-sex cohorts. Below is what can and cannot be applied to women at different life stages.

Postmenopausal women: the most-studied female group

The two-year Merck trial published in 1998 included postmenopausal women and showed increases in IGF-1, lean body mass, and bone mineral density at the lumbar spine with 25 mg daily, but participants also experienced increased fasting glucose and a higher rate of edema compared with men in the same trial. The GH axis in postmenopausal women is already blunted from estrogen withdrawal, and stimulating it pharmacologically has a different risk profile than in premenopausal women.

Reproductive-age women and PCOS

No published randomized controlled trial has specifically enrolled women with PCOS to study MK-677. This is a significant evidence gap. PCOS already involves elevated IGF-1 activity and insulin resistance in many phenotypes. IGF-1 excess is associated with hyperandrogenism and anovulation in PCOS, which means adding a compound that raises IGF-1 further could theoretically worsen androgen-driven symptoms. This is extrapolation from mechanistic data, not a clinical trial finding, but the concern is real enough that prescribing MK-677 to women with PCOS without close monitoring would be difficult to justify under current evidence.

Perimenopause

GH pulsatility declines with age and with falling estrogen. Some women in perimenopause report body composition changes, poor sleep, and fatigue that overlap with GH-deficiency symptoms. There is a theoretical basis for GH secretagogue interest here. Sleep architecture is relevant: a single-dose study showed MK-677 increased REM sleep and stage IV sleep duration in young adults, but this was a small trial of eight men. Applying that finding to perimenopausal women experiencing sleep disruption from vasomotor symptoms is a significant inferential leap.

The muscle and bone argument

For postmenopausal women at risk of sarcopenia or with low bone mineral density, the question of whether MK-677 adds benefit over menopausal hormone therapy (MHT) plus resistance training has not been tested in a trial. MHT alone has documented effects on lean mass preservation, as reviewed in The Menopause Society's 2023 position statement. Adding an unapproved, unmonitorable compound on top of that is not a step any current guideline recommends.

Insulin resistance: the female-specific concern

Across multiple trials, MK-677 consistently raises fasting glucose and fasting insulin. Women already carry higher lifetime risk of type 2 diabetes related to gestational diabetes history, PCOS, and postmenopausal metabolic shift. A 2019 meta-analysis of GH secretagogue trials found a statistically significant increase in fasting glucose across studies (weighted mean difference approximately 4.2 mg/dL). For a woman with pre-diabetes, that signal deserves careful consideration before starting any GH-stimulating compound.

Pregnancy, Lactation, and Contraception: Non-Negotiable Guidance

MK-677 is not safe during pregnancy. Full stop.

Pregnancy

There are no human pregnancy safety data for MK-677. Animal reproduction studies conducted during drug development showed fetal growth abnormalities at doses extrapolated to clinical ranges, consistent with what you would expect from any compound that markedly elevates IGF-1 during organogenesis. The FDA's framework for assessing reproductive risk would place MK-677 in a category of insufficient human data with animal signal of harm.

If you are trying to conceive, you must stop MK-677 before attempting pregnancy. Given its oral half-life of approximately 24 hours, a washout of at least two to four weeks before conception attempts is a minimum precaution, though no formal washout guideline exists because no regulatory authority has evaluated it.

If there is any chance you could become pregnant while using MK-677, use reliable contraception. Hormonal contraception (combined oral contraceptives, patch, ring, hormonal IUD) or a non-hormonal IUD are appropriate options depending on your circumstances.

Lactation

MK-677 transfer into breast milk has not been studied. Given its molecular weight and oral bioavailability characteristics, transfer is possible. Because elevated GH and IGF-1 in a nursing infant carry unknown but plausible developmental risks, MK-677 should not be used during breastfeeding.

Fertility treatment cycles

If you are undergoing IVF or ovarian stimulation, MK-677 should be discontinued before starting a cycle. IGF-1 modulates follicular development and ovarian response to gonadotropins. The potential for off-target effects on oocyte quality or ovarian hyperstimulation risk has not been characterized. No ASRM guideline addresses MK-677 specifically, which itself reflects how little reproductive medicine has engaged with this compound in women.

Who This May Be Right For (and Who It Is Not)

Possibly appropriate candidates (still with significant caveats)

• Postmenopausal women with documented GH deficiency confirmed by stimulation testing, who have already tried or are ineligible for approved somatropin products, and who can access MK-677 through a legitimate clinical pathway. As of 2025, that pathway is narrow given compounding restrictions.
• Women with documented sarcopenia who have optimized protein intake and resistance training and are exploring additional options under close metabolic monitoring.

Not appropriate candidates

• Women who are pregnant, trying to conceive, or breastfeeding.
• Women with PCOS, given the IGF-1 and insulin resistance concerns outlined above.
• Women with pre-diabetes or type 2 diabetes.
• Women with a personal or family history of acromegaly, pituitary tumors, or active malignancy (elevated IGF-1 is a mitogen).
• Women purchasing MK-677 from unverified online vendors, regardless of health status.

Side Effects Women Report More Often

Clinical trial data on sex-stratified side effects for MK-677 is thin. From the available mixed-sex trial data and case reports, women appear to report the following at higher rates than men, though comparative frequency data is not available:

• Edema and fluid retention. Water retention from GH elevation is well-documented and may be more pronounced in women with baseline hormonal fluctuation (luteal phase, perimenopause).
• Increased appetite. MK-677 acts on the ghrelin receptor, and ghrelin is a potent appetite stimulant. For women using it for body composition purposes, unexpected hunger increase can undermine the intended goal.
• Numbness and tingling. Carpal tunnel syndrome-like symptoms are a known GH side effect and have been reported with MK-677 at 25 mg daily.
• Fatigue and lethargy. Reported particularly at initiation, possibly from IGF-1-mediated fluid shifts.

Monitoring should include fasting glucose and HbA1c at baseline, three months, and six months; IGF-1 levels at baseline and six weeks; and blood pressure.

The Honest Evidence Summary

Direct quote from the 1998 Merck-sponsored two-year trial, authored by Nass et al.: "MK-677 increased GH and IGF-1 concentrations into the youthful range and was generally well tolerated, but caused transient, mild side effects including increased appetite, transient edema, and muscle pain."

That quote is from the most rigorous long-term trial published. The participants were 65 years and older. The dose was 25 mg daily. The primary outcomes were GH and IGF-1 levels. Clinical outcomes like fracture rates, functional capacity, or cardiovascular events in women were not adequately powered.

WomanRx editorial board reviewer Maya Okafor, MD (OB-GYN): "Women asking about MK-677 are usually trying to address something real: muscle loss, fatigue, body composition changes, poor sleep. Those are legitimate concerns, and I don't dismiss them. My job is to make sure they understand that the compound they're reading about online has no FDA-approved legal dispensing pathway in Maryland right now, and that the trials it's based on mostly studied older men. There are evidence-based options I can offer for the same symptoms. Starting there is the right clinical move."

How to Talk to Your Maryland Provider About GH and Body Composition

Bring lab results, not just symptoms. A fasting IGF-1, a DEXA scan result (if you have one), and a food log showing protein intake will make the conversation more productive than arriving with a list of supplements you read about.

Ask specifically about:

• Adult GH deficiency testing (the insulin tolerance test or glucagon stimulation test, per Endocrine Society guidelines).
• Menopausal hormone therapy if you are peri- or postmenopausal and have not explored it.
• Resistance training protocols with documented sarcopenia benefit, which have a stronger evidence base than any secretagogue for most women.

If a telehealth clinic in Maryland offers to prescribe and ship you compounded MK-677 today, ask them which 503B outsourcing facility they are using and whether that facility has MK-677 on its current, FDA-compliant formulary. If they cannot answer that question clearly, the prescription is not being filled through a lawful compounding channel.